JPRN-C000000291已完成2 期
Study of Docetaxel followed by FEC as primary systemic chemotherapy for operable breast cancer (JBCRG-03) - JBCRG-03(DOC-FEC as primary systemic chemotherapy)
Japan Breast Cancer Research Group (JBCRG)0 个研究点目标入组 137 人开始时间: 2005年11月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 137
研究概览
简要总结
Of the 132 patients assessable for pathologic response, 23% experienced a pCR and 6% had a near pCR (few remaining cancer cells), resulting in a quasi-pCR of 29%. Clinical RR following the initial DOC regimen was 64%. The overall clinical RR after completion of FEC was 79%. Breast-conserving surgery was performed in 79% of patients.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 60years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •Drug hypersensitivity Severe complication Inflammatory breast cancer Double cancer Bilateral breast cancer
研究者
相似试验
已完成
2 期
A randomized study of Docetaxel + Cyclophosphamide (TC), 5-fluorouracil + Epirubicin + Cyclophosphamide (FEC)-TC and TC-FEC as preoperative chemotherapy for hormone receptor positive and HER2 negative primary breast cancer JBCRG-09hormone receptor positive and HER2 negative primary breast cancerJPRN-UMIN000003283Japan Breast Cancer Research Group (JBCRG)195
终止
3 期
Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast CancerBreast CancerNCT00912444Shanghai Jiao Tong University School of Medicine102
已完成
2 期
Validation study of FEC followed by docetaxel as preoperative chemotherapy in primary beast cancer (JBCRG-02')Primary breast cancerJPRN-C000000320Japan Breast Cancer Reaserch Group (JBCRG)20
已完成
1 期
Phase I/II trial of Nedaplatin and Docetaxel for advanced Squamous cell carcinoma of the lungchamotherapy-naive advanced squamous cell carcinoma of the lungJPRN-UMIN000001227ational Cancer Center Hospital East Thoracic Oncology Division24
进行中（未招募）
1 期
A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer. - PROSTY trialMetastatic Hormone Refractory Prostate Cancer.MedDRA version: 8.1Level: PTClassification code 10060862Term: Prostate cancerEUCTR2004-004295-37-IEAll-Ireland Cooperative Oncology Research Group360